role of tipranavir in treatment of patients with multidrug-resistant hiv
Clicks: 7
ID: 251483
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
1.8
/100
7 views
6 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #90 of 91 articles by views in liver transplantation : official publication of the american association for the study of liver diseases and the international liver transplantation society
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Joshua D Courter1,2, Colleen J Teevan1, Michael H Li1, Jennifer E Girotto1,2, Juan C Salazar1,2,31University of Connecticut School of Pharmacy, Storrs, 2Connecticut Children’s Medical Center, Hartford, 3University of Connecticut School of Medicine, Hartford, Connecticut, USAAbstract: The worldwide emergence of multidrug-resistant human immunodeficiency virus (HIV)-1 strains has the driven the development of new antiretroviral (ARV) agents. Over the past 5 years, HIV-entry and integrase inhibitor ARVs, as well as improved non-nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), have become available for treatment. It is important to assess how these new ARVs might be most judiciously used, paying close attention to viral susceptibility patterns, pharmacodynamic parameters, and the likelihood that patients will adhere to their therapy. Herein we review published material in Medline, EMBASE, and ISI for each antiretroviral agent/classes currently approved and summarize the available data on their efficacy, safety, and pharmacologic parameters. We focus on the role of tipranavir, a recently approved nonpeptidic PI, for treating HIV-infected children, adolescents, and adults with a history of multidrug-resistant HIV.Keywords: tipranavir, HIV, multidrug resistance
| Reference Key |
courter2010therapeuticsrole
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Joshua D Courter;Colleen J Teevan;Michael H Li;et al |
| Journal | liver transplantation : official publication of the american association for the study of liver diseases and the international liver transplantation society |
| Year | 2010 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.